drugset / Trial / NCT02171325
Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.
Timeline
- Start
- 2014-06
- Primary completion
- 2021-06
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 60 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 65 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 70 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 75 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 80 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 85 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 90 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 95 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 100 mg/m2 | — |